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Jeffery J. Auletta,1,2 Kenneth R. Cooke,3,4 Luis A. Solchaga,5 Robert J. Deans,6
Wouter van’t Hof6Regenerative stromal cell therapy (RSCT) has the potential to become a novel therapy for preventing and
treating acute graft-versus-host disease (GVHD) in the allogeneic hematopoietic stem cell transplant
(HSCT) recipient. However, enthusiasm for using RSCT in allogeneic HSCT has been tempered by limited
clinical data and poorly defined in vivo mechanisms of action. As a result, the full clinical potential of RSCT
in supporting hematopoietic reconstitution and as treatment for GVHD remains to be determined. This
manuscript reviews the immunomodulatory activity of regenerative stromal cells in preclinical models of
allogeneic HSCT, and emphasizes an emerging literature suggesting that microenvironment influences RSC
activation and function. Understanding this key finding may ultimately define the proper niche for RSCT in
allogeneic HSCT. In particular, mechanistic studies are needed to delineate the in vivo effects of RSCT in
response to inflammation and injury associated with allogeneic HSCT, and to define the relevant sites of
RSC interaction with immune cells in the transplant recipient. Furthermore, development of in vivo imaging
technology to correlate biodistribution patterns, desired RSC effect, and clinical outcome will be crucial to
establishing dose-response effects and minimal biologic dose thresholds needed to advance translational
treatment strategies for complications like GVHD.
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Culture adherent stem cells have been isolated
from many adult and postnatal tissue sources, includ-
ing bone marrow (BM), cord blood (CB), adipose,
and others. These stem cells share the common prop-
erty of low immunogenicity and active immunomodu-
lation, and depending on isolation and expansion
conditions, can participate in the regeneration of in-
jured tissue. The multipotent mesenchymal stem cell
(MSC) is the most widely studied in both preclinical
and clinical studies. We propose to classify these ad-
herent stem cell cultures as regenerative stromal cells
(RSCs), for the purpose of reviewing their role in tissue
repair and immunomodulation in allogeneic hemato-
poietic stem cell transplantation (HSCT).
Allogeneic HSCT results in graft-versus-tumor
(GVT) effects, which eradicate residual malignant
cells via immunologic mechanisms. However, benefi-
cial GVT activity shares similar immune pathways
with deleterious acute graft-versus-host disease
(aGVHD). Therefore, separating these disparate
immune responses within the allogeneic HSCT recip-
ient remains a major challenge [1]. Consequently,891
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death following allogeneic HSCT [2]. Current immu-
nosuppressive therapy used to prevent and/or treat
GVHD is suboptimal, and can be detrimental by pro-
moting infectious sequelae and relapse of malignant
disease [2,3]. Regenerative stromal cell therapy
(RSCT) offers the unique potential to facilitate hema-
topoiesis and engraftment, to modulate alloimmunity
without compromising GVT effects, and to promote
immune reconstitution and tissue repair [4]. In this re-
gard, RSCT is emerging as a novel form of therapy for
aGVHD. This review will examine the immunobiol-
ogy of RSCT as it relates to the pathophysiology of
aGVHD and focus on the role that relevant inflamma-
tory microenvironments have on RSC activation and
function.aGVHD
The underlying pathophysiology of aGVHD in-
volves donor T cell activation by host alloantigens
and secretion of donor-derived cytotoxic cytokines
that have an impact on host tissues [5-7]. The resultant
‘‘cytokine storm’’ not only targets endothelium pri-
marily within the gut, liver, and skin [8], but also dam-
ages the thymus [9] and lungs [10] of the transplant
recipient. Endothelial cell (EC) injury is caused by
both the conditioning regimen and the cytotoxic T
cells induced by aGVHD [11].Whether EC activation
is a consequence of antigen presentation by ECs them-
selves or by immune effector cells via cross presenta-
tion is controversial [12]. Yet, injured endothelium is
a significant source of chemokines and growth factors,
which recruit additional immune cells to sites of injury
thereby propagating tissue damage in the host.
Murine models of allogeneic HSCT have been in-
strumental in defining the immune responses underly-
ing aGVHD [13]. Specifically, mouse models have
identified cellular and soluble factors that mediate
and regulate the GVHD response. Consequently,
these mediators have become targets for second-line
therapies used to treat steroid-resistant aGVHD
[14-16]. However, immunomodulatory therapy is of-
ten suboptimal in treating aGVHD, and can increase
the risk for opportunistic infections [17] and, poten-
tially, disease relapse [18]. Therefore, novel strategies
are needed to reduceGVHD, to preserve GVT effects,
and to facilitate engraftment and immune reconstitu-
tion.POTENTIAL ROLES FOR RSCT IN
ALLOGENEIC HSCT
In addition to hematopoietic progenitor cells, the
BM microenvironment contains nonhematopoietic
progenitor cells that give rise to the stroma of theBM and have the potential to differentiate into cells
from other connective tissue lineages such as bone,
cartilage, and fat. Such stromal cells are not a homoge-
neous population of cells and have different regenera-
tive potential [19,20]. This review will focus on two
specific regenerative stromal cell subpopulations exist-
ing within the BM compartment, namely, MSCs and
multipotent adult progenitor cells (MAPCs) (Figure 1).
We refer to their common properties and therapeutic
strategies using the term RSCT as described before,
and provide a focused review on their relevant proper-
ties for use in allogeneic HSCT.
MSCs arenonhematopoietic cells (CD342CD452)
with surface expression for CD73, CD90, and CD105,
and can differentiate in vitro into osteoblasts, chondro-
blasts, and adipocytes [21]. Human MSCs have
constitutive surface expression of major histocompati-
bility complex (MHC) class I and interferon (IFN)-
g-inducible expression of MHC class II. MSCs can be
expanded ex vivo from BM mononuclear cells (BM
MNC) obtained from animals and humans. Cells with
similar characteristics can also be expanded from
adipose tissue [22], umbilical CB (UCB) [23], and pla-
centa [24]. In humans, the frequency of MSCs ranges
from 1 MSC per 10,000 BM MNCs in newborns to 1
MSC per 250,000 BMMNCs in adults [25].
In contrast to HSCs, BM-derived MSCs can be
culture expanded until reaching replicative senescence
up to 386 4 population doublings (PD) (PD
time5 50-60 hours) albeit with loss in differentiation
capacity [25-27]. For example, extensive subcultivation
can reduce BM-derived MSC differentiation potential
and can induce onset of senescence [28] or even cellu-
lar apoptosis [29]. Consistent immunomodulation and
differentiation of BM-derived human MSCs is well
maintained for up to 5 passages of cell expanded
medium comprised of Dulbecco’s Modified Eagles
Media-Low Glucose and 10% fetal bovine serum
(FBS) [30,31]. However, isolation and expansion
methods vary greatly among different laboratories,
and such differences may influence MSC immunomo-
dulation [32].
Like MSCs, MAPCs can be expanded from mouse
and human BM MNCs [33,34], and can be grown to
clinical scale (MultiStem) [35]. Expanded MAPCs
possess tissue regenerative and immunomodulatory
properties similar to MSCs [36,37], consistent with
their position as a developmental progenitor to the
MSC. In contrast to MSCs, MAPCs have higher sur-
face expression of CD49d and broader ex vivo pluripo-
tency, with evidence of differentiation into cellular
elements of all primitive germ line layers (mesoderm,
endoderm, and ectoderm) [38]. Human MAPCs ex-
press telomerase and are capable of more extensive
expansion (75 PDs) than humanMSCs [39], particu-
larly when cultured under hypoxic culture conditions.
Expansion of undifferentiated human MAPCs from
Figure 1. Mesenchymal stromal cells: mesenchymal stem cells and multipotent adult progenitor cells. General comparisons between 2 specific types of
mesenchymal stromal cells are provided. Refer to text for details. Photographs of MSCs [162] and MAPCs [36] reprinted with permission. Prochymal
is a mesenchymal stem cell (MSC)-based product GMP-manufactured by Osiris Therapeutics, Inc. (Baltimore, MD). MultiStem is a multipotent adult
progenitor cell (MAPC)-based product GMP-manufactured by Athersys, Inc. (Cleveland, OH). Note: 11 Population doubling (PD) limit is defined as the
maximum number of PDs in which the respective stromal cell maintains telomere length, cytogenetic stability, andmultilineage differentiation potential in
ex vivo culture conditions. These limits are variable and dependent upon the expansion protocol used, the age and condition of the donor, and the fre-
quency of stromal cells in the bone marrow. Abbreviations: MSC, mesenchymal stem cell; MAPC, multipotent adult progenitor cell; mM, micron.
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growth factor (PDGF), epidermal growth factor
(EGF), and 2% FBS [39] with the requirement that
cell density and oxygen tension must be tightly con-
trolled [38].Hematopoiesis and Engraftment
MSCs function as paracrine mediators [40], pro-
ducing cytokines, chemokines, and extracellular matrix
proteins that support in vitroHSC survival and prolif-
eration and in vivo HSC engraftment. In particular,
MSCs constitutively express mRNA for interleukin
(IL)-6, -7, -8, -11, -12, -14, -15, macrophage colony
stimulating factor (M-CSF), flt-3 ligand (FL), and
stem cell factor [41]. Ex vivo stimulation with IL-1a
upregulates mRNA expression of granulocyte colony
stimulating factor (G-CSF), M-CSF, leukemia inhibi-
tory factor, IL-1, IL-6, IL-8, and IL-11, and induces
mRNA expression of granulocyte macrophage colony
stimulating factor (GM-CSF) in human BM-derived
MSCs [42]. Moreover, MSCs express the stem cell-
derived factor 1 (SDF-1, CXCL12) receptor CXCR4
[43,44], which likely contributes to MSC homing
and augmentation of HSC engraftment via SDF-1
gradients.
MSCs can support ex vivo expansion of CD341
umbilical cord blood cells [45] and improve human
hematopoiesis in nonobese diabetic/severe combined
immunodeficienty (NOD-SCID) mice followingcotransplantation with human HSCs. Noort and col-
leagues [46] used human fetal lung (FL)-derived
CD341 cells to generate MSCs and cotransplanted
them with a limiting number of UCB CD341 cells.
They observed a 3- to 4-fold increase in the level of hu-
man hematopoietic engraftment in NOD-SCID mice
given FLMSCs compared to those that did not receive
MSCs. Angelopoulou et al. [47] cotransplanted human
BM-derived MSCs with mobilized blood CD341 cells
and found enhanced human myeloid and megakaryo-
cytic engraftment in NOD-SCID mice. Last, Maitra
and colleagues [48] reported increased frequency and
level of human hematopoietic engraftment in mice co-
transplanted with humanMSCs and a limiting number
of human UCB cells.
The profile of proteins secreted by MAPCs also
supports their ability to exert hematopoietic effects
via paracrine activity [37,49]. Serafini and colleagues
[50] showed that BM-derived murine MAPCs, albeit
at greater absolute numbers than HSCs, functionally
reconstituted the hematopoietic system in vivo in
NOD-SCID mice. In a myeloablative syngeneic rat
HSCT model, allogeneic expanded MAPCs were
infused 2 days after HSCT and weekly thereafter for
a total of 5 administrations. MAPC infusion did not af-
fect hematopoietic recovery in transplant recipients,
nor cause allogeneic antibody production, T cell sensi-
tization, or ectopic tissue formation [51]. Tolar et al.
[52] demonstrated that both host irradiation and
natural killer (NK) cell depletion resulted in greater
894 Biol Blood Marrow Transplant 16:891-906, 2010J. J. Auletta et al.distribution and engraftment of donor MAPC infu-
sions in mice. Last, Jiang and colleagues [19] also
showed enhanced MAPC engraftment and broader
distribution profiles for MAPCs in the context of
host irradiation, suggesting that MAPC homing and
engraftment during HSCT can be increased with in-
duction of tissue injury and release of proinflammatory
cytokine and chemokines.
Based upon results from these preclinical trans-
plant models, MSC infusions have been tested in clin-
ical autologous [30] and allogeneic [53]HSCT settings
and found to be safe and well tolerated. Importantly,
no published study has demonstrated a higher inci-
dence of graft failure associated with MSC infusions.
Instead some studies have suggested that MSC infu-
sions have decreased the incidence of graft failure
over historic controls and even enhanced neutrophil
and platelet engraftment in select adult [54,55] and
pediatric HSCT recipients [56], with sustained donor
MSC chimerism in pediatric transplant recipients
[57]. However, MSC infusions have not been reported
to confer a consistent engraftment advantage during
HSCT [58,59].
Regeneration and Repair
MSCs have been shown to differentiate into, to re-
pair, and to support mesengenic tissue, particularly
marrow and connective tissues. Moreover, MSCs
may also mediate thymic repair, given their role in
thympoiesis and positive selection of T lymphocytes
[60], a potential benefit in young transplant patients
[61]. In contrast to MSCs, MAPCs have broader
in vitro differentiation capacity, and therefore greater
theoretical potential for tissue repair in the setting of
HSCT. For example, in the presence of vascular endo-
thelial growth factor (VEGF), MAPCs differentiate
into an endothelial progenitor cell phenotype [34] as
well as hepatocyte-like cells [62], both of which ulti-
mately assume their respective differentiated cell type
morphology and function. In contrast to MSCs,
MAPC differentiation into hematopoietic stem cells
has been demonstrated in vivo in a NOD-SCIDmodel
of allogeneic MAPC engraftment [50].
RSCT-mediated in vivo tissue repair and regener-
ation has been suggested, but not clearly demon-
strated, in preclinical [63] and clinical [64] allogeneic
HSCT. Evidence for direct stromal cell-mediated tis-
sue repair in the setting of clinical HSCT is lacking
[65], as paracrine effects of RSCs likely mediate and/
or influence repair [66].
Immunomodulation
RSCs as a broad class of stem cells possess an in-
trinsic ability to modulate innate and adaptive immune
responses. Importantly, MSCs alter antigen-present-
ing cell (APC) development, maturation, and function,and inhibit alloreactive T cell responses (see excellent
reviews by Rasmusson [67] and Le Blanc and Ringden
[68]). Effects of MSCs on immune cell activation and
response have mostly been demonstrated in ex vivo cul-
ture conditions, limiting our knowledge of their in vivo
effects. Common mechanisms through which MSCs
suppress APC and/or T cell activation and function in-
clude direct cell-cell contact, production of regulatory
soluble factors, and induction of regulatory cellular
phenotypes [69].
Effects on innate immunity: focus on dendritic
and NK cells
Dendritic cells (DCs) are potent APCs for naı¨ve T
cells and have critical roles in donor T cell activation
during aGVHD [70,71]. Toll-like receptor (TLR)
activation causes maturation of peripheral DCs, in-
creasing their surface expression of adhesion and cos-
timulatory molecules, shifting their function from
antigen-capturing to antigen-processing cells, and
promoting their interaction with naı¨ve T cells by en-
hancing expression of CCR7 and migration to second-
ary lymph nodes [72]. MSCs affect DC differentiation,
activation, and function and inhibit differentiation of
monocytes into myeloid DCs [73,74]. MSCs upregu-
late IL-10 production by plasmacytoid DCs [75], de-
crease pro-inflammatory IL-12 and tumor necrosis
factor (TNF)-a production [75,76], and decrease co-
stimulatory surface markers, such as MHC class II
and CD83 [74,75]. In this context, MSCs could alter
the ability of DCs to function as potent APCs during
GVHD. As an example, application of MSCs in
a murine allogeneic BMTmodel resulted in decreased
CCR7 expression and reduced numbers of DCs
migrating to secondary lymphoid organs [77].
MSCs also inhibit NK cell proliferation and cyto-
kine (IL-2, IL-15, and IFN-g) production, but are
themselves susceptible to NK cell-mediated lysis
[78,79]. Interestingly, IFN-g protects MSCs from
NK lysis [78], suggesting that an inflammatory micro-
environment may modify MSC function towards elim-
inatingNK cells (see section on ‘‘Mesenchymal stromal
cells and micro-environment’’). Furthermore, MSCs
could also potentially modulate DC function through
their effects on NK cell function [80,81].
Similar to MSCs, murine MAPCs have constitu-
tive low-level expression ofMHC class I that likely un-
derlies their susceptibility to NK cell-mediated lysis
[52]. In contrast, expanded rat or human MAPCs
were not found to be susceptible to NK lysis [82]
(van’t Hof, unpublished data). Mouse MAPC MHC
class I expression can be upregulated by IFN-g
in cell culture, correlating with the use of total
body irradiation and subsequent enhanced MAPC
engraftment and biodistribution following allogeneic
HSCT [52] and suggesting that proinflammatory mi-
croenvironments can modify MAPC function. Also,
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sion on DCs [83].
Effects on adaptive immunity: focus on T cells
In general, human MSCs inhibit in vitro T cell ac-
tivation and proliferation induced by mitogens, recall
antigens, and alloantigens [48,75,84-87]. Effects of
MSC-mediated T cell suppression are independent
fromHLAmatching betweenMSCs and lymphocytes,
are dose-dependent, and are generalized across T cell
subtypes (naı¨ve versus memory and CD41 versus
CD81). Furthermore, MSC effects are reversible (i.e.,
do not result in T cell apoptosis), are associated with
downregulation of T cell activation markers (CD25,
CD38, CD69), and are reported to bemediated by var-
ious soluble inhibitory factors (heme oxygenase 1,HO-
1 [88]; hepatocyte growth factor, HGF [89]; HLA-G5
[90]; indoleamine 2,3-dioxygenase, IDO [91]; IL-10
[75,92]; prostaglandin E2, PGE2 [75]; and transform-
ing growth factor (TGF-b) [93]). Lastly, MSCs pro-
duced in some laboratories reportedly shift T cell
function to a more regulatory phenotype [75,94].
Like MSCs, MAPCs do not stimulate in vitro
alloreactiveT cell responses [51,52] andhave reversible,
dose-dependent and soluble factor-mediated immuno-
suppressive effects on T cell alloreactivity [82,83].
Specifically, expanded rat MAPCs mediate IDO-
dependent T cell suppression [82], whereas murine
MAPCs utilize PGE2-dependent mechanisms for
T cell suppression [83]. Furthermore, murine MAPC
Tcell suppression associateswith attenuation in inflam-
matory cytokine production and costimulatory mole-
cule expression on T cells [83].Use of RSCT for GVHD
Because of their relative ease for ex vivo expansion,
their infusion safety profile, and their immunosuppres-
sive properties, RSCs are being tested clinically to pre-
vent and to treat GVHD. However, efficacy remains
inconsistent throughout both preclinical models
(Table 1) and clinical trials (Table 2), which have
used RSCT as therapy for GVHD.
Preclinical experience
UseofRSCT for preventing and treatingGVHDin
preclinical models has shown mixed benefit (Table 1).
Such inconsistency in effect likely reflects the variability
in disease models with respect to how alloreactivity is
induced (minor versus major MHC mismatch, T cell
dose), the conditioning regimenused (lethal versus sub-
lethal radiation), and the types of hematopoietic and
regenerative stem cell types given (stem cell source
and method of expansion, stem cell dose, and timing
and mechanism of delivery). In addition, preclinical
transplant models have shown that in vivo effects of
MSCs are not necessarily predicted by their in vitroeffects [95,96] and, in contrast to their intended effect,
some studies have even shown that MSC infusions
may cause graft rejection [97,98].
Despite these drawbacks, preclinical models have
been helpful in revealing key aspects of RSCT in the
context of allogeneic HSCT. First, the level of host
immuncompetency is an important factor that can in-
fluence the use of RSCT. For example, murine MHC-
mismatched MSCs are either rejected [99] or induce
graft rejection [73] in the context of absent or minimal
sublethal radiation, respectively. Preclinical studies
have also revealed that the intended benefit of RSCT
is independent of the source or subset of RSCs used
as well as the haplotype match between the stromal
cells used and the host, as long as the host is sufficiently
immunocompromised (Table 1). Finally, survival ben-
efit in using RSCT closely associates with infusion of
cells early posttransplant and after induction of
GVHD. Specifically, administration of MSCs [100-
103] and MAPCs [82,83] after HSC administration
confers a greater survival benefit than coadministra-
tion with HSCs [95,96,98]. Furthermore, RSC infu-
sion after 21 days of HSC infusion does not confer
a survival advantage [22,104]. Collectively, these data
suggest an early posttransplant ‘‘window’’ of time
when RSCs are infused, which uniquely affects RSC
activation and function.
However, direct translational application of pre-
clinical findings into clinical approaches remains lim-
ited for several reasons. First, most preclinical GVHD
models are driven by CD41 T cell activities [13],
whereasCD81 Tcell subsetsmay be the primarymedi-
ators of clinical aGVHD in the allogeneic transplant
setting [105]. Second, preclinicalmodelsmay be slanted
toward diverse immunologic tendencies. For example,
C57Bl/6 mice display prototypic Th1 responses,
whereas BALB/c mice are prone to Th2 responses
[106]. Therefore, choice of donor and recipient mouse
strain combinations can potentially have an impact on
the efficacy of RSCT as a consequence of exposure to
different immunomodulatory milieus. In support, pre-
clinicalGVHDmodels suggest trends inmeasuredben-
efit based upon mouse strains (Table 1). Six studies in
mice and 2 studies in rats report survival advantage
and improved clinical GVHD scores in animals given
RSCT [22,51,100-104,107]. In contrast, 4 studies
show no GVHD benefit; and these studies all utilize
BALB/c or BALB/c-derived F1 as transplant recipients
[83,95,96,98]. One study using BALB/c recipients did
show protective activity of MSCs, but only when they
were administered at the time of transplant and not in-
fused simultaneously with T cells [107]. It is possible
that variations in the immunologic context encountered
by the infused stromal cells have anmay impact on their
benefit. Yet, other factors including the degree ofMHC
mismatch betweendonorTcells and theBALB/c recip-
ients must also be considered. However, at minimum,
Table 1. Application of Regenerative Stromal Cells in Animal Models of Allogeneic Hematopoietic Stem Cell Transplant
Publication GVHD Model Stromal Cell Source Stromal Cell Regimen Results
Highfill et al 2009 [83] B6/ BALB\c
850 cGy
10 M BM, 2 M T cells
Mouse MAPC 500 K MAPC on day 1 i.v. or intrasplenic,
prior to T cells on day 2
PGE2-dependent GVHD protection after intrasplenic
administration
Kovacsovics- Bankowski
et al 2008 [51]
Buff/ BuffLewF1
700 cGy
20 M BM, 7 M T Cells
Lewis rat MAPC 2.5 M MAPC day 1 or day 1 + 5 Survival benefit after 1 or 2 administrations.
Tian et al 2008 [100] Fischer/Wistar
850 cGy
10 M BM, 20 M SPL
Fischer rat BM MSC 2 M MSC on day 1 after HSCT Survival benefit and reduction of T cells, Th1/Th2 ratio
and increase of CD4+/CD25+ cells.
Badillo et al 2008 [96] B6/CB6F1
900 cGy
10 M BM, 30 M SPL
Mouse stromal progenitor cells
(mSPC)
150 K or 1 M mSPC on day 0 with BMTor
day 2; 50 K SPC at days 0, 7, and 14; or
150 K SPC at days 10 or 21
No survival or clinical score benefit observed in any
prophylaxis or treatment regimens.
Prigozhina et al 2008 [98] B6/CB6F1
650 cGy
10 M BM, 25 M SPL
Mouse BM/placental/UCB- MSC 50 K or 500 K MSC on days 0+7+14 No survival benefit observed for any MSC type tested.
Ren et al 2008 [101] B6/ B6C3HF1
1300 cGy
5 M BM, 5 M SPL
Mouse BM MSC
(WT, IFN-gR1 KO, or iNOS KO)
500 K MSC on days 1 + 3 GVHD survival dependent on preexposure to IFN-g +
either TNF-a, IL1a, or IL1b and iNOS.
Polchert et al 2008 [102] BALB/c/ B6
1000 cGy
Not reported
Mouse BM MSC
(WT, IFN-g-deficient)
100 or 500 K MSC on days 0, 2, 20, or 30 Survival benefit after administration on day 2, 20, or 30,
increased by IFN-g priming. IFN-g -deficient T cells
insensitive to GVHD protection by MSC.
Min et al 2007 [103] B6/ B6D2F1
1100 cGy
10 M BM, 20 M SPL
Mouse BM MSC
(± IL-10 transduction)
1 or 2 M MSC on day 1 or days 1, 3, and 5 IL-10-dependent benefit for survival, clinical scores, and
reduced IFN-g serum. No survival benefit by
unmodified MSC at day 1, or days 1, 3, and 5.
Tisato et al 2007 [104] hPBMC/NOD-Scid 250 cGy
20 M huPBMC
UCB-MSC 3 MUCB-MSC day 0, or days 0, 7, 14 and 21,
or week 5, 6, 7, 8
Benefit after infusion on days 0, 7, 14, and 21, but not
after infusion on weeks 5, 6, 7, 8.
Yanez et al 2006 [22] B6/ B6D2F1
1100 cGy
10 BM, 20 M SPL
hAd-MSC, hBM-MSC, mAd-MSC 50 K mAd-MSC on days 0, 7, and 14, or days
14, 21, and 28
Benefit after infusion on day 0, 7, and 14, but not after
administration on days 14, 21, and 28.
Sudres et al 2006 [95] B6/ BALB\c
800 cGy
3 M BM, 100 K T cells
Mouse BM-MSC 500 K, 3 or 4 M MSC at 215 min prior to
BMT
No survival benefit observed.
Minor GI protection seen with 4 M dose.
Chung et al 2004 [107] C3H/He/ BALB\c
875 cGy
10 M BM, 5 M SPL
Mouse BM-MSC 100 K MSC on day 0 with BMT Survival benefit when coinfused with BM, but not when
coadministered with BM and SPC.
Ad indicates adipose; BM, bone marrow; B6, C57Bl/6; Buff, Buffalo rat; h, human; K, thousand; Lew, Lewis rat; m, mouse; M, million; PBMC, peripheral blood mononuclear cell; SPC, stromal progenitor cell; SPL,
splenocytes; GI gastrointestinal; GVHD, graft-versus-host disease.
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Table 2. Published Clinical Experience of MSCs to Prevent or to Treat Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Publication Indication Trial Specifics MSC Regimen Endpoints and results
Kebriaei et al
2009 [111]
De novo acute GVHD (II-IV) N5 32 patients (21/10 M/F)
Median age 52 years (34-67)
21 grade II, 8 grade III and 3 grade
IV acute GVHD
Allogeneic (unrelated, unmatched) BM-MSC
2 or 8 M/kg + steroids
dose 1 at 24-48 hours after GVHD,
dose 2 at +3 days
 No infusion-related toxicities or ectopic
tissue formation
 94% initial response by day 28 (77% CR and
16% PR)
 No difference in safety or efficacy between
low- and high-MSC dose
von Bonin et al
2009 [112]
Steroid-refractory, severe acute GVHD N5 13 patients (7/6 M/F)
Median age 58 years (21-69)
2 grade III, 11 grade IV acute GVHD
0.9 M/kg (0.6-1.1 M)
2 doses third-party BM-MSC expanded in
platelet lysate-containing media
dose 1 at median 16 days after aGVHD onset
 No infusion-related side effects
 All MSCs used impaired PHA-stimulated
CD4+ proliferation
 Only 2 patients did not require additional
escalation of concomitant
immunosuppressive therapy
 5/7 patients with initial response required
additional MSC therapy
 4/9 deaths attributed to GVHD
Le Blanc et al
2008 [110]
Steroid-refractory, severe acute GVHD N5 55 patients (34/21 M/F)
Median age 22 years (0.5-64)
5 grade II, 25 grade III, and 25 grade IV acute
GVHD
1.4 M/kg MSC (0.4-9)
1 dose (27); 2 doses (22); 3-5 MSC doses (6)
5 Sib, 18 Haplo, 69 HLA-MM MSC
 No infusion-related side effects
 30/55 complete response, 9 partial, CR show
survival benefit over PR/NR at 2 years 53%
versus 16%
 No relation between response and MSC HLA
match
Muller et al
2008 [109]
Immunologic complications after allo-HSCT
in pediatric patients
N5 7 patients(M/F not specified)
Median age 14 years (4-17)
2 acute GHVD and 3 chronic GVHD
0.4 to 3 M/kg MSC
1 (4), 2 (2), and 3 doses (1)
5 Haplo, 2 third-party parental MSC
 No infusion-related side effects (at 29 months
max)
2 patients with severe acute GVHD did not
progress to chronic GVHD
 1/3 slight improvement of chronic GVHD
Fang et al
2007 [161]
Steroid-refractory, severe acute GVHD N5 6 patients (2/4 M/F)
Median age 39 years (22-49)
2 grade III and 4 grade IV acute GVHD
1 M/kg Adipose MSC
1 dose (5), 2 doses (1)
2 Haplo, 4 HLA-MM MSC
 No infusion-related side effects
 5/6 complete response
 4/6 survival (18-90 months posttreatment)
Ringden et al
2006 [31]
Steroid-refractory, severe acute GVHD N5 9 patients (7/1 M/F),
Median age 56 years (8-61),
2 grade II (1 chronic), 5 grade III, and 1 grade IV
acute GVHD, 1 grade III after DLI
1 M/kg MSC (0.7 to 9)
1 dose (6); 2 doses (4)
2 Sib, 6 Haplo, 4 HLA-MM MSC
 No infusion-related side effects
 6/8 complete response
 5/8 survival (2-36 months posttreatment)
Lazarus et al
2005 [53]
GVHD prevention N5 46 patients (24/22 M/F),
Median age 45 years (19-61)
1-5 M/kg Sib MSC
4 hr pre-HSCT
 No infusion-related side effects or ectopic
tissue formation
 No increase in incidence or severity of GVHD
CR indicates complete response; DLI, donor lymphocyte infusion; Haplo, haploidentical donor; M, million; M/F, male/female; HLA-MM, HLA mismatched donor; NR, no response; PR, partial response; Sib, HLA-iden-
tical sibling; GVHD, graft-versus-host disease, MSC, mesenchymal stem cell; HSCT, hematopoietic stem cel transplant; DLI, donor leukocyte infusion.
Criterion for inclusion in table was published clinical trial and/or experience with >5 patients.
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need for utilizing multiple models in parallel to permit
more generalized interpretation for the benefit of
RSCT.Clinical experience
Clinical experience using RSCs is also limited, and
results are equally as mixed as the published preclinical
experience (Table 2). Initial success using maternal
haploidentical MSCs in a pediatric HSCT patient
with steroid and second-line immunomodulatory
therapy-resistant aGVHD [108] has driven the
broader application of BM-derived MSC therapy dur-
ing allogeneic HSCT [31,53,109-111]. The 2 largest
published series of patients treated with BM-derived
MSCs have shown complete and/or partial responses
(CR, PR) to MSC therapy in 70% (n5 39/55) and
90% (n5 29/32) of patients receiving MSCs for
steroid-resistant [110] or MSCs in combination with
steroids for de novo aGVHD [111], respectively. Fur-
thermore, steroid-resistant GVHD patients having
a CR to MSC therapy also had improved OS and de-
creased treatment-related mortality compared to pa-
tients with a PR or no response [110]. Although
variable doses of MSCs were administered, the median
single dose of MSCs in the EBMT Development
Group experience (1.4 106 MSCs/kg) [110] was sim-
ilar in therapeutic efficacy to the single dose used in the
randomized, opened-label phase II Osiris trial (2 106
MSCs/kg) [111]. In the Osiris trial efficacy using the
clinical-grade MSC product Prochymal was similar
between high- (2 doses, each 8 106 MSCs/kg) and
low-dosed study groups (2 doses, each 2 106
MSCs/kg) [111]. Results from the phase III Osiris clin-
ical trials have recently been reported via press release
from the company (September 8, 2009 http://invest-
or.osiris.com/releasedetail.cfm?ReleaseID5408763).
In both studies weekly or biweekly MSC administra-
tions were given to patients for 4 weeks with individual
dosing at 2 106 MSCs/kg, the lower end of MSC
dosing compared to previous published experiences
[110,111]. Neither the steroid-refractory (Protocol
280, NCT00366145, n5 260) nor the newly diag-
nosed (Protocol 265, NCT00562497, n5 192)
aGVHD trials reached the primary endpoint of
durable CR. However, select patients with either ste-
roid-refractory liver or gastrointestinal GVHD who
received Prochymal were reported to have signifi-
cantly improved response rates (76% versus 47%,
P5 .026, n5 61 and 88% versus 64%, P5 .018,
n5 71, respectively). Lower MSC dosing and/or dif-
ferences in treatment regimens across institutions
may have affected these results. Other smaller sized
trials in pediatrics [109] and in adults [112] have also
shown either modest or transient response, respec-
tively, following MSC administration.Together, these clinical studies highlight the need
for continued preclinical evaluations to optimize dos-
ing strategies, to define biodistribution profiles, and
to assess efficacy. Moreover, the inconsistent effects
of RSCT shown in preclinical models as well as clinical
trials suggest the fundamental need to understand
mechanisms for RSC activation and function, specifi-
cally in relationship to the microenvironment into
which RSCs are infused and to where these cells
ultimately home.RSC and Their Microenvironment
How RSCs respond to and interact with their in
vivo microenvironment remain largely undefined, but
is critical to understanding how these cells function
in GVHD and to improving their efficacy in prevent-
ing and treating GVHD. This section will focus on
how RSCs may functionally respond to the inflamma-
tory microenvironment they encounter and will also
review an emerging literature that defines how the mi-
croenvironment can modulate RSC activation and
function.
Toll-like receptors
Within the microenvironment, constitutive and
inducible cytokines, chemokines, growth factors, and
other soluble factors are produced by resident and mi-
grant hematopoietic and nonhematopoietic cells.
Pathogen-associated molecular patterns and other
danger signals for inflammation and injury are recog-
nized by TLRs on the surface of APCs [113]. Once ac-
tivated, TLRs signal through MyD88-dependent and
MyD88-independent signaling cascades resulting in
NF-kB dependent gene transcription of proinflamma-
tory cytokines and chemokines [114]. Activation of
TLR2 and TLR4 on hematopoietic progenitor cells
has recently been shown to influence progenitor cell
differentiation [115,116]. Murine BM-derived MSCs
[117] and human BM and adipose-derived MSCs
[118] also express TLR2 and TLR4. TLR2 and
TLR4 are important in sensing and initiating host de-
fense responses to injury and to inflammation [119],
and are upregulated by disease states like sepsis
[120,121] and by soluble factors including cytokines
[122,123] and other TLR ligands [124,125]. Hypoxic
culture conditions can increase TLR2 mRNA expres-
sion on human adipose-derived MSCs [118], whereas
LPS can upregulate levels of TLR4 mRNA and
TNF-a production from ex vivo stimulated rat BM-
derived MSCs [126].
LPS further promotes inflammation by inducing
production of reactive oxygen species, an effect bal-
anced by antioxidant enzymes like heme-oxygenase 1
(HO-1) [127,128]. HO-1 modulates innate [129] and
adaptive [130] immune cell function by attenuating in-
flammation [131] and potentially preventing GVHD
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press T cell proliferation [88]. Thus, LPS could poten-
tially activate both TLR and HO-1 signaling [133]
cascades within MSCs to modulate LPS-induced in-
flammation associated with aGVHD. Furthermore,
combining agents like the synthetic triterpenoids,
which are potent inducers of HO-1 [134], with
MSCs might also augment the beneficial effects of
HO-1 induction for the treatment of GVHD [135].
TLR ligation also influences MSC proliferation,
differentiation, and immune function. Cho and
colleagues [118] have demonstrated that TLR2 (Staph-
ylococcus aureus peptidoglycan) and TLR4 (LPS)
ligands promote osteogenic differentiation of human
adipose-derived MSCs, effects dependent upon TLR
signaling cascades [136]. Using murine MSCs, Pevs-
ner-Fischer and colleagues [117] have shown that
TLR2 agonist, Pam3Cys, augments MSC prolifera-
tion and inhibits MSC differentiation into osteoblasts,
adipocytes, and chondrocytes. In addition, TLR2-
stimulated murine MSCs retain their ability to inhibit
T cell proliferation. In contrast, ligation of TLR3 and
TLR4 on human BM-derived MSCs reversed their
ability to inhibit T cell proliferation without affecting
MSC phenotype or differentiation, a process shown to
be dependent upon Notch signaling [137]. In human
BM-derived MSCs, ex vivo stimulation with TLR3 li-
gand, poly(I:C), induced NF-lB-dependent cytokines
and chemokines as well as enhanced MSC transwell
migration, suggesting that TLR3 ligation is critically
involved in mediating human MSC migration [138].
Opitz and colleagues [139] have also demonstrated
the importance of TLR3 ligation in enhancing
MSC-mediated immunosuppression via IDO induc-
tion requiring type I IFN signaling.
Cytokines and chemokines
As important as the effect of MSCs on immune ef-
fector cell function is the crosstalk effect that immune
effector cells and their inducible factors may have on
MSC activation and function. For example, MSCs
require activation via soluble factors like IL-1b and
IFN-g to mediate T cell inhibition. IL-1b produced
by CD141 cells activates human MSC-mediated
in vitro T cell suppression via TGF-b1 [93]. Similarly,
IFN-g added to human MSC cultures induces MSC
MHC class II expression and enhances their inhibitory
activity in mixed lymphocyte cultures [84].
Levels of IFN-g may also affect MSC function as
immunosuppressive cells or immunoactivating APCs.
In one report, low concentrations of IFN-g upregulate
MHC class II expression onMSCs and result in MSCs
functioning as APCs, whereas increasing concentra-
tions of IFN-g decrease MHC class II expression
and shift MSC function into alloinhibitory cells
[140]. IFN-g activation of MSCs and subsequent
alloinhibition has been shown to be mediated byIDO [141], an effect due to the accumulation of tryp-
tophan metabolites [142]. IFN-g pretreatment also in-
creases murine MSC crosspresentation of exogenous
antigen via MHC class I to induce CD81 cytotoxicity,
further suggesting that cytokine exposure modulates
MSC APC function [143]. Finally, IFN-g and TLR
priming induces MSC proinflammatory cytokine
production, which may increase local recruitment of
innate effector cells that may subsequently be modu-
lated by MSCs themselves [144]. Together, these re-
sults suggest an immunomodulatory role for MSCs
in the LPS-induced inflammatory microenvironments
present during sepsis [145] and after GVHD induc-
tion.
MSCs express chemokine receptors and adhesion
molecules involved in migration to sites of tissue injury
[146,147]. MSC migration is broad in the absence of
injury, but preferential in response to injury and in-
flammation [36,148], an effect mediated by chemokine
receptors and gradients. For example, low-dose radia-
tion upregulates CCR2 expression on MSCs, enhanc-
ing their migration into tumor beds [149]. Once
homed to sites of injury or inflammation, MSCs have
been shown to act like neutrophils in their ability to
extravasate from blood vessels through coordinated
rolling and adhesion [150]. Furthermore, matrix
metalloproteinases released by MSCs degrade the en-
dothelial vessel basement membrane to allow extrava-
sation into damaged tissue [151]. Chemokine receptor
expression on MSCs may further be influenced by the
inflammatory microenvironment and even the very
soluble factors produced by MSCs themselves
[152,153]. Thus, paracrine and autocrine induction
of chemokines and cytokines likely culminate to
modulate MSC function within and migration to
a particular microenvironment.
Dynamic immunomodulation between
mesenchymal stromal cells and their
microenvironment
The allure for using RSCT to treat immune-
mediated diseases such as GVHD [110] is tempered
by studies suggesting that MSCs may not be as im-
mune-privileged [99] or alloinhibitory [97] as generally
perceived. MSC immune function seemingly is a deli-
cate balance between immune privilege and suppres-
sion [154]. Plasticity in MSC function likely reflects
the microenvironment in which these cells reside and
to which they ultimately migrate. Consequently,
‘‘net’’ MSC immune function may be determined by
themicroenvironment in which indigenous andmigra-
tory hematopoietic and nonhematopoietic cells and
their associated constitutive and inducible soluble fac-
tors combine to modify MSC activation and function.
In turn, ‘‘activated’’ MSCs modulate the activation,
function, and maturation of immune cells. Therefore,
a dynamic interplay ensues between mesenchymal
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Figure 2. Emerging model of mesenchymal stromal cell activation and function in the context of tissue injury and/or inflammation. Migrating hemato-
poietic and nonhematopoietic cells home to sites of tissue injury and inflammation along gradients created by inflammatory chemokines and danger
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modulatory milieu (see Figure 2).
Recent publications provide evidence for and
insight into a ‘‘dynamic immunomodulation model’’
between MSCs and their microenvironment, espe-
cially in the context of murine allogeneic HSCT and
GVHD. Ren and colleagues [101] demonstrated
IFN-g-activated, MSC-mediated, suppression of T
cells via nitric oxide (NO) production. Specifically,
IFN-g in combination with proinflammatory cyto-
kines (IL-6, IL-1a, and TNF-a) within the microenvi-
ronment was necessary to induce MSC production of
chemokines (CXCL-9, MIG, and CXCL-10, IP-10).
These MSC-derived chemokines are hypothesized to
bring alloreactive T cells in close proximity to
MSCs, wherein NO produced by MSCs then sup-
presses T cell activity. To further demonstrate the crit-
ical roles of IFN-g and NO, MSCs derived from micedeficient in IFN-gR1 or iNOS were used and these
cells failed to prevent GVHD.
Polchert and colleagues [102] also showed that
IFN-g is necessary to activate MSC-mediated preven-
tion of GVHD, and that timing of MSC infusion was
critical to GVHD prevention. Specifically, MSC infu-
sion at the time of BM transplantation (day 0 [D0]) did
not preventGVHD.However,MSC infusions given at
D2 or D20 significantly improved OS and histologic
evidence for GVHD, suggesting the need for MSCs
to be primed by their microenvironment to be effec-
tive. Moreover, MSCs pretreated with increasing con-
centrations of IFN-g were infused into transplant
recipients and shown to prevent GVHD in a dose-
dependent manner. Taken together, these preclinical
results seem to recapitulate the clinical experience us-
ing BM-derived MSCs in that MSCs given at the time
of transplantation do not significantly improve the
Biol Blood Marrow Transplant 16:891-906, 2010 901Regenerative Stromal Cell Therapyincidence of severe GVHD [53], whereas MSCs given
at the time of GVHD onset have therapeutic benefit
[110], likely reflecting critical differences in the micro-
environments encountered by the RSCs at these differ-
ent times following allogeneic HSCT.FUTURE DIRECTIONS
The emerging concept of microenvironment influ-
ence on RSC activation and function should be applied
to future mechanistic study using preclinical models to
evaluate therapeutic approaches with direct clinical ap-
plication to allogeneic HSCT. For example, defining
the influence of RSCT on inflammatory tissue as
a site of initiating naı¨ve T cell allo-sensitization may
reveal that RSCT influences disease regionally in addi-
tion to its local immunomodulatory effects within sec-
ondary lymphoid organs. Specifically, administering
RSCT early after inflammatory tissue damage versus
later after T-effector amplification in the secondary
lymphoid organs may critically influence RSC homing
and effect. For example, Highfill et al. [83] have re-
ported GVHD benefit, but only with direct intra-
splenic administration; as MAPCs intravenously
injected at the time of transplant did not show
GVHD and survival benefit. Another important ques-
tion is whether ex vivo manipulation of RSCs can
preferentially alter their biodistribution and function
in different microenvironments. In this regard, Min
et al. [103] have shown that infusion of MSCs overex-
pressing IL-10 enhance protection from GVHD; and
Polchert et al. [102] have reported increased MSC
efficacy after IFN-g priming.
Intravenous injection remains the most convenient
and widely used route of RSCT administration. Yet
few published animal models address where infused
RSCs home and/or reside [52,83,95,96], and only
one study addresses effects of alternative routes of ad-
ministration on biodistribution [52]. Defining homing
patterns that have an impact on RSC interactions with
target cells is critical to establishing dose dependency
and timing of administration to optimize RSCT
effects. Following the observation by Highfill and
colleagues [83], ex vivo manipulation of RSCT or the
use of alternative dosing regimens could guide homing
of sufficient numbers of RSCs to localized sites
of GVHD to reduce exposure to higher numbers of
third-party immunomodulatory cells that may ad-
versely mediate tolerogenic effects and increase the
risk of malignant disease relapse or metastasis
[59,155]. In addition to encountering hematopoietic
cells within immunomodulatory milieus, systemically
administered RSCs may also interact with endothe-
lium and epithelium [150,156]. Damaged endothelium
serves as a significant source of soluble factors that re-
cruit additional immune cells to sites of injury, therebycontributing to propagation of host tissue damage in
the context of GVHD [157]. Preliminary in vitro find-
ings show that MAPCs can inhibit activation of endo-
thelial cells by inflammatory triggers such as TNF-a,
IL-1b, and LPS, and diminish endothelial expression
of cytokines and adhesion molecules involved lympho-
cyte extravasation [158]. In addition, human MAPCs
inhibit fucosyltransferase 7 (Fut7) and surface expres-
sion of Lewis antigen (CD15s) on activated lympho-
cytes [159,160], resulting in reduced binding of
T cells to activated endothelium (van’t Hof, unpub-
lished observations). Therefore, RSCT may prevent
GVHD-mediated tissue damage by downregulating
cytotoxic lymphocyte extravasation and/or cytokine
production from damaged endothelium.CONCLUSIONS
RSCT has the potential to become a novel treat-
ment for GVHD following allogeneic hematopoietic
stem cell transplantation. However, key issues that
likely have an impact on the efficacy of RSCT require
further investigation.
 Standardization in expansion protocols and admin-
istration of RSC products is needed to ensure prod-
uct homogeneity and consistency within and across
clinical studies.
 Refined and sensitive analysis of RSC biodistribu-
tion at the level of single cell detection is needed
to identify anatomical sites where RSCs interact
with immune effector cells. Development of these
imaging technologies would also permit correlation
of biodistribution patterns with RSC activity and
outcome measures.
 Establishing relevant potency assays for RSC prod-
ucts would define dose and delivery strategies and
may reveal additional ways for exploiting RSC
immunomodulation and tissue repair capacity,
including ex vivomanipulation to direct RSC immu-
nomodulatory activity by enhancing delivery to
target areas.
 Sufficient biomarkers have yet to be identified to
define optimal timing of RSC administration as
well as to follow clinical response to determine the
need for repeat RSC dosing. Similarly, delineating
dose-response effects and a consistent and minimal
biologic-dose threshold is critical for advancing
clinical treatment strategies.
 Finally, defining whether immunomodulatory
effects of RSCs at the site of inflammatory tissue in-
jury and within secondary lymphoid organs differ, as
these two sites may utilize different anti inflamma-
tory and immunomodulatory pathways.
In closing, the proper niche for RSCT in alloge-
neicHSCT is still undefined. Yet, the clinical potential
902 Biol Blood Marrow Transplant 16:891-906, 2010J. J. Auletta et al.and promise of RSCs may ultimately be achieved
through more advanced mechanistic study into their
in vivo effects and through well-designed clinical trials
demonstrating their clear benefit.ACKNOWLEDGEMENTS
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